<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01286402</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-09-0681</org_study_id>
    <nct_id>NCT01286402</nct_id>
  </id_info>
  <brief_title>Double-blind, Placebo-Controlled Pilot Study of Bupropion to Promote Smoking Cessation During Pregnancy</brief_title>
  <official_title>Double-blind, Placebo-Controlled Pilot Study of Bupropion to Promote Smoking Cessation During Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilstrap, Larry C, M.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to gather preliminary effectiveness and safety data on the use of
      bupropion for smoking cessation in pregnant women attending a community prenatal clinic. This
      study will provide critical preliminary data in preparation for a larger, Phase III clinical
      trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, parallel group design will be used to allow a rigorous
      preliminary assessment of the feasibility, effectiveness, and safety of bupropion SR
      (sustained release; packaged as Zyban by GlaxoSmithKline) in promoting smoking cessation
      among women in their second and third trimester of pregnancy. Fifty pregnant smokers will be
      randomized to receive an 8-week course of either bupropion SR or matching placebo tablets.
      Both groups will receive evidence-based smoking cessation counseling. The primary smoking
      outcome will be 7-day point prevalence abstinence with cotinine validation at the end of the
      treatment. Secondary outcomes include enrollment, retention, and compliance rates; continuous
      abstinence from end of treatment through the 2 week followup; continuous abstinence from
      birth to 2nd week postpartum followup; self-reported reduction in number of cigarettes smoked
      per day; and maternal side effects and perinatal/neonatal outcomes. Preliminary smoking
      cessation and safety outcomes will be assessed for the generation of evidence-based
      hypotheses regarding clinical benefit of bupropion for pregnant smokers in preparation fo a
      larger trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>7-day Point Prevalence Smoking Abstinence With Cotinine Validation at the End of Treatment</measure>
    <time_frame>1 week post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Enrollment, Retention and Compliance Rates</measure>
    <time_frame>1 year (estimated)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous Abstinence From End of Treatment Through the 2 Week Followup</measure>
    <time_frame>at two week followup visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous Abstinence From Birth to 2nd Week Postpartum Followup</measure>
    <time_frame>at 2nd week postpartum followup visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported Reduction in Number of Cigarettes Smoked Per Day</measure>
    <time_frame>at 1 week post treatment and at 2 week postpartum visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Side Effects</measure>
    <time_frame>during treatment, end of treatment and at 2 week postpartum visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perinatal/Neonatal Outcomes</measure>
    <time_frame>at neonatal discharge from hospital following delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Bupropion SR (sustained release)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group receiving bupropion SR medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion SR</intervention_name>
    <description>150mg, taken orally, taken daily for the 1st 3 days
300mg, taken orally, taken daily for the rest of the 8 weeks of drug treatment</description>
    <arm_group_label>Bupropion SR (sustained release)</arm_group_label>
    <other_name>Zyban, Wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>-Avicel PH 302, Emcocel 50M, Cab-O-Sil M5P, Magnesium Stearate (appearance, taste, and dosing instructions were identical to the bupropion group), i.e., 1 pill orally, taken daily for the 1st 3 days; 2 pills, taken orally, taken daily for the rest of the 8 weeks of drug treatment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women ≥ 18 years of age

          -  Gestational age between 14 and 26 weeks confirmed by ultrasound

          -  Currently smoking ≥ 5 cigarettes per day

        Exclusion Criteria:

          -  Abnormal liver function tests

          -  History of or current seizure disorder or closed head injury with loss of
             consciousness

          -  Known hypersensitivity to bupropion

          -  Any psychiatric disorder requiring psychotropic medication

          -  Current anorexia or bulimia

          -  Use of monoamine oxidase (MAO) inhibitors or discontinuation within the past 2 weeks

          -  Major Depressive Disorder or current suicidal risk

          -  Use of any illicit substances since receiving knowledge of pregnancy

          -  Regular use of alcohol (&gt;1 drink/week on average)

          -  Unstable medical problems, such as liver or renal disease, uncontrollable
             hypertension, and lupus

          -  Twins or other multiple gestation

          -  Fetal abnormality on the 14 week ultrasound

          -  Plans to deliver at a hospital other than Memorial Hermann

          -  Inability to communicate with research staff or make study visits due to lack of phone
             or transportation access

          -  Participation in another clinical study which may affect study outcomes

          -  Current use of any Nicotine Replacement Therapy (NRT), bupropion, or varenicline
             (Chantix)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela L Stotts, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston, Professional Building</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2011</study_first_submitted>
  <study_first_submitted_qc>January 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2011</study_first_posted>
  <results_first_submitted>June 30, 2015</results_first_submitted>
  <results_first_submitted_qc>January 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2016</results_first_posted>
  <last_update_submitted>January 5, 2016</last_update_submitted>
  <last_update_submitted_qc>January 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Angela Stotts</investigator_full_name>
    <investigator_title>Associate Professor - Family Medicine</investigator_title>
  </responsible_party>
  <keyword>Smoking cessation during pregnancy</keyword>
  <keyword>bupropion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bupropion SR (Sustained Release)</title>
          <description>Group receiving bupropion SR medication
Bupropion SR: - 150mg (1 pill), taken orally, taken daily for the 1st 3 days
- 300mg (2 pills), taken orally, taken daily for the rest of the 8 weeks of drug treatment</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Group receiving placebo
-Avicel PH 302, Emcocel 50M, Cab-O-Sil M5P, Magnesium Stearate (appearance, taste, and dosing instructions were identical to the bupropion group), i.e., 1 pill orally, taken daily for the 1st 3 days; 2 pills, taken orally, taken daily for the rest of the 8 weeks of drug treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bupropion SR (Sustained Release)</title>
          <description>Group receiving bupropion SR medication
Bupropion SR: - 150mg, taken orally, taken daily for the 1st 3 days
- 300mg, taken orally, taken daily for the rest of the 8 weeks of drug treatment</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Group receiving placebo
-Avicel PH 302, Emcocel 50M, Cab-O-Sil M5P, Magnesium Stearate (appearance, taste, and dosing instructions were identical to the bupropion group), i.e., 1 pill orally, taken daily for the 1st 3 days; 2 pills, taken orally, taken daily for the rest of the 8 weeks of drug treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.2" spread="5.6"/>
                    <measurement group_id="B2" value="26.7" spread="5.9"/>
                    <measurement group_id="B3" value="26.9" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title># cigs smoked in past 30 days</title>
          <units>cigarettes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.8" spread="11.1"/>
                    <measurement group_id="B2" value="10.7" spread="5.4"/>
                    <measurement group_id="B3" value="10.7" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age started smoking</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.8" spread="3.0"/>
                    <measurement group_id="B2" value="17.3" spread="9.0"/>
                    <measurement group_id="B3" value="17.5" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Carbon monoxide reading</title>
          <units>parts per million</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.8" spread="3.7"/>
                    <measurement group_id="B2" value="15.2" spread="17.5"/>
                    <measurement group_id="B3" value="12.0" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>7-day Point Prevalence Smoking Abstinence With Cotinine Validation at the End of Treatment</title>
        <time_frame>1 week post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupropion SR (Sustained Release)</title>
            <description>Group receiving bupropion SR medication
Bupropion SR: - 150mg, taken orally, taken daily for the 1st 3 days
- 300mg, taken orally, taken daily for the rest of the 8 weeks of drug treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group receiving placebo
-Avicel PH 302, Emcocel 50M, Cab-O-Sil M5P, Magnesium Stearate (appearance, taste, and dosing instructions were identical to the bupropion group), i.e., 1 pill orally, taken daily for the 1st 3 days; 2 pills, taken orally, taken daily for the rest of the 8 weeks of drug treatment</description>
          </group>
        </group_list>
        <measure>
          <title>7-day Point Prevalence Smoking Abstinence With Cotinine Validation at the End of Treatment</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Enrollment, Retention and Compliance Rates</title>
        <time_frame>1 year (estimated)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Continuous Abstinence From End of Treatment Through the 2 Week Followup</title>
        <time_frame>at two week followup visit</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Continuous Abstinence From Birth to 2nd Week Postpartum Followup</title>
        <time_frame>at 2nd week postpartum followup visit</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self-reported Reduction in Number of Cigarettes Smoked Per Day</title>
        <time_frame>at 1 week post treatment and at 2 week postpartum visit</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal Side Effects</title>
        <time_frame>during treatment, end of treatment and at 2 week postpartum visit</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perinatal/Neonatal Outcomes</title>
        <time_frame>at neonatal discharge from hospital following delivery</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bupropion SR (Sustained Release)</title>
          <description>Group receiving bupropion SR medication
Bupropion SR: - 150mg (1 pill), taken orally, taken daily for the 1st 3 days
- 300mg (2 pills), taken orally, taken daily for the rest of the 8 weeks of drug treatment</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Group receiving placebo
-Avicel PH 302, Emcocel 50M, Cab-O-Sil M5P, Magnesium Stearate (appearance, taste, and dosing instructions were identical to the bupropion group), i.e., 1 pill orally, taken daily for the 1st 3 days; 2 pills, taken orally, taken daily for the rest of the 8 weeks of drug treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia secondary to ABO incompatibility</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Newborn readmission for respiratory failure on day of life 5</sub_title>
                <description>MOTHER HAD UPPER RESPIRATORY SYMPTOMS SUGGESTIVE OF INFECTION. INFANT HAD DECREASED FEEDING, LETHARY, DEHYDRATION AND DEVELOPED APNOEA AND WAS INTUBATED FOR RESPIRATORY SUPPORT. EVENT THOUGHT NOT BE RELATED TO STUDY MEDICATION AND IS RESOLVED.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angela Stotts, PhD, PI</name_or_title>
      <organization>University of Texas Health Science Center at Houston</organization>
      <phone>713-500-7590</phone>
      <email>Angela.L.Stotts@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

